HbO

Hemoglobin Oxygen Therapeutics LLC

News

February 13, 2019
Hemoglobin Oxygen Therapeutics LLC Announce Updated Results From The Netherlands Leading Liver Transplant Hospital

Pilot study shows ten donor livers previously rejected for transplant, salvaged with new machine perfusion technology using Company’s lead product, Hemopure®. To date, results show 100 percent transplant and survival rates for all patients. SOUDERTON, PA and GRONINGEN, The Netherlands. February 13 2019 —  Hemoglobin Oxygen Therapeutics LLC (HbO2 Therapeutics), a biopharmaceutical company specializing in oxygen…

January 21, 2019
Record number of liver transplants at UMCG due to new perfusion technique

​​In 2018, the UMCG carried out 73 liver transplants. On average around 60 liver transplants were done in the past few years, and in 2017 there were 56. This increase of around 20 percent is almost completely due to the use of normothermic machine preservation of donor livers that were rejected for transplantation in the…

January 16, 2019
The National Institute for Health and Care Excellence (NICE) approves organ perfusion for use on the NHS, stating that perfusion machines could increase the number of livers that can be safely used for transplantation

​A new procedure for storing livers donated for transplant has been hailed a “game changer” and approved for use on the NHS. The National Institute for Health and Care Excellence (NICE) say perfusion machines could increase the number of livers that can be safely used for transplantation. They store donated livers at body temperature, which…

November 8, 2018
Hemopure® to be evaluated in groundbreaking clinical study of trauma patients in the prehospital setting, sponsored by the United States Department of Defense, and coordinated by Stellenbosch University

Patient enrollment expected to commence in mid 2019 Hemopure, the Company’s oxygen carrying solution, could potentially be an integral part of trauma resuscitation practice in remote locations SOUDERTON, Pa., Nov. 8, 2018 /PRNewswire/ — Hemoglobin Oxygen Therapeutics LLC (HbO2 Therapeutics), a private biopharmaceutical company specializing in oxygen therapeutics (previously known as “blood substitutes”) for both…

November 1, 2018
SU awarded contract to direct large clinical study in trauma resuscitation

Patient enrolment expected to commence by mid-2019 and conclude by 2021 Ground-breaking clinical research that has the potential to change pre-hospital care of civilian and military trauma victims worldwide Emergency medicine experts from Stellenbosch University (SU) are embarking on a large, multi-institutional clinical trial in partnership with the United States Department of Defence, to evaluate…

February 16, 2018
Red blood cell substitutes

Nina Notman reports on progress towards products that can, when necessary, replace donor red blood cells

October 18, 2017
Hemoglobin Oxygen Therapeutics LLC Announces the World’s First Human Liver Transplantation After Ex-Situ Normothermic Machine Perfusion Using Hemopure

SOUDERTON, Pa., Oct. 18, 2017 /PRNewswire/ — Hemoglobin Oxygen Therapeutics LLC (HBO2 Therapeutics) is the leading developer of hemoglobin based solutions that increase the oxygen carrying capacity of blood. The Company announced today the 1st human organ transplant of a previously rejected liver, reconditioned ex-situ with a warm perfusion solution oxygenated with Hemopure prior to transplantation….

October 10, 2017
UMCG makes rejected donor liver suitable for transplantation

For the first time in the Netherlands, a patient has received a donor liver that was optimized in a perfusion machine after having been rejected for transplantation. The patient is making an excellent recovery. The transplant was part of an experiment in which donor livers considered unsuitable for transplantation are ‘refurbished’ in a perfusion machine….